indazoles has been researched along with n-(3-fluoro-4-((1-methyl-6-(1h-pyrazol-4-yl)-1h-indazol-5 yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Ajamie, R; Buchanan, SG; Graff, JR; Heidler, SA; Hui, YH; Huss, KL; Konicek, BW; Manro, JR; Peek, VL; Shih, C; Stewart, JA; Stewart, TR; Stout, SL; Uhlik, MT; Um, SL; Walgren, RA; Wang, Y; Wu, W; Yan, L; Yan, SB; Yang, WJ; Zhong, B | 1 |
| Bi, C; Credille, KM; Donoho, GP; Manro, JR; Peek, VL; Walgren, RA; Wijsman, JA; Wu, W; Yan, L; Yan, SB | 1 |
| Arif, Q; Hasina, R; Husain, AN; Kawada, I; Mueller, J; Salgia, R; Smithberger, E; Vokes, EE | 1 |
| Barat, S; Bozko, P; Chen, X; Götze, J; Hanert, F; Malek, NP; Plentz, RR; Scholta, T; Wilkens, L | 1 |
| Alley, K; Alvarez, AA; Arslan, AD; Bell, JB; Bi, Y; Cheng, SY; Clymer, J; Davuluri, RV; Eckerdt, FD; Goldman, S; Horbinski, C; Hussain, H; James, CD; Magnusson, LP; Nakano, I; Platanias, LC | 1 |
| Birnbaum, A; Cohen, RB; Denlinger, CS; Giles, J; He, AR; Hwang, J; Lewis, N; Moser, B; Mynderse, M; Niland, M; Plimack, ER; Sama, A; Sato, T; Walgren, R; Wallin, J; Zhang, W | 1 |
| Bang, YJ; Bendell, J; Carlsen, M; Chow, KH; Chung, HC; de Miguel, MJ; Gandhi, L; Italiano, A; Lin, CC; Patnaik, A; Schmidt, S; Su, WC; Szpurka, AM; Vangerow, B; Xu, X; Yap, TA; Yu, D; Zhao, Y | 1 |
3 trial(s) available for indazoles and n-(3-fluoro-4-((1-methyl-6-(1h-pyrazol-4-yl)-1h-indazol-5 yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
| Article | Year |
|---|---|
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Blood Vessels; Cell Line, Tumor; Cell Proliferation; Humans; Indazoles; Mice; Mutation; Niacinamide; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Receptor Protein-Tyrosine Kinases; Tetrazoles; Xenograft Model Antitumor Assays | 2013 |
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Proliferation; Cetuximab; Cholangiocarcinoma; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoplasm Staging; Niacinamide; Protein Kinase Inhibitors; Ramucirumab; Squamous Cell Carcinoma of Head and Neck | 2019 |
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Benzimidazoles; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Prognosis; Ramucirumab | 2021 |
4 other study(ies) available for indazoles and n-(3-fluoro-4-((1-methyl-6-(1h-pyrazol-4-yl)-1h-indazol-5 yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
| Article | Year |
|---|---|
Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Gene Expression; Hepatocyte Growth Factor; Humans; Indazoles; Lung Neoplasms; Mice; Neoplasm Metastasis; Niacinamide; Oncogene Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-met; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer.
Topics: Amino Acid Sequence; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Enzyme Activation; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Indazoles; Lung Neoplasms; Mice; Niacinamide; Peptides; Proto-Oncogene Proteins c-met; Receptor Protein-Tyrosine Kinases; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Female; Humans; Indazoles; Mice, Nude; Molecular Targeted Therapy; Neoplasm Invasiveness; Niacinamide; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Signal Transduction | 2016 |
MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glioblastoma; Humans; Hyaluronan Receptors; Indazoles; Intracellular Signaling Peptides and Proteins; Mice; Neoplasm Grading; Neoplastic Stem Cells; Niacinamide; Phosphorylation; Protein Serine-Threonine Kinases; Survival Analysis; Xenograft Model Antitumor Assays | 2016 |